Skip to main content

BiTE and ADCs for cancer therapy

This Journal of Hematology & Oncology series covers bi-specific T-cell engagers (BiTE) and antibody-drug conjugates (ADCs) for cancer therapy. The series, which is no longer open for submissions, will include reviews, editorials, and first in-human clinical trial papers.


  1. Chimeric antigen receptor (CAR)-modified T cells and BiTEs are both immunotherapies which redirect T cell specificity against a tumor-specific antigen through the use of antibody fragments. They demonstrated r...

    Authors: Julien Edeline, Roch Houot, Aurélien Marabelle and Marion Alcantara

    Citation: Journal of Hematology & Oncology 2021 14:65

    Content type: Review

    Published on:

  2. Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that redirect T cells to tumor surface antigens. While efficacious against certain hematological malignancies, limited bioavaila...

    Authors: Johannes P. W. Heidbuechel and Christine E. Engeland

    Citation: Journal of Hematology & Oncology 2021 14:63

    Content type: Review

    Published on:

  3. Therapeutic antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor responses in multiple types of cancers. However, only a subse...

    Authors: Ming Yi, Jing Zhang, Anping Li, Mengke Niu, Yongxiang Yan, Ying Jiao, Suxia Luo, Pengfei Zhou and Kongming Wu

    Citation: Journal of Hematology & Oncology 2021 14:27

    Content type: Research

    Published on:

  4. B7-H3, an immune-checkpoint molecule and a transmembrane protein, is overexpressed in non-small cell lung cancer (NSCLC), making it an attractive therapeutic target. Here, we aimed to systematically evaluate t...

    Authors: Jie Liu, Shuo Yang, Bihui Cao, Guangyu Zhou, Fengjuan Zhang, Yuan Wang, Rixin Wang, Lipeng Zhu, Ya Meng, Cong Hu, Hui Liang, Xu Lin, Kangshun Zhu, Guokai Chen, Kathy Qian Luo, Lijun Di…

    Citation: Journal of Hematology & Oncology 2021 14:21

    Content type: Research

    Published on:

  5. Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing properties of chemotherapy. They are commonly descri...

    Authors: Carmen Criscitiello, Stefania Morganti and Giuseppe Curigliano

    Citation: Journal of Hematology & Oncology 2021 14:20

    Content type: Review

    Published on:

  6. Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and child...

    Authors: Jorge E. Cortes, Marcos de Lima, Hervé Dombret, Elihu H. Estey, Sergio A. Giralt, Pau Montesinos, Christoph Röllig, Adriano Venditti and Eunice S. Wang

    Citation: Journal of Hematology & Oncology 2020 13:137

    Content type: Review

    Published on: